CDKL5 Deficiency Disorder – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
CDKL5 deficiency disorder is a genetic disorder that causes seizures, developmental delay, and severe intellectual disability. Seizures typically begin within a few months after birth and are difficult to control with medications. Most children have 1 to 5 seizures every day. It is an X-linked dominant disorder. This disorder includes many features of classic Rett syndrome (including developmental problems, loss of language skills, and repeated hand wringing or hand washing movements) but also causes recurrent seizures beginning in infancy.
·
Some CDKL5 mutations change a single protein
building block (amino acid) in a region of the CDKL5 protein that is critical
for its kinase function. Other mutations lead to the production of an
abnormally short, nonfunctional version of the protein.
·
There are currently no approved drugs to treat
CDKL5 Deficiency, save for Anti-Epileptic Drugs (AEDs) to treat epileptic
seizures.
·
The anti-epileptic drugs have limited
efficacy, pointing to a strong need to develop new treatment strategies for
patients
Thelansis’s “CDKL5 Deficiency Disorder
Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential CDKL5
Deficiency Disorder treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of CDKL5 Deficiency Disorder across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
CDKL5 Deficiency Disorder Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment